设为首页         

资讯内容 Content

[ESC2011]左主干冠脉病变的治疗选择——Eeckhout 博士专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

作者:Eeckhout 编辑:国际循环网 时间:2011/8/30 16:53:37    加入收藏
 关键字:左主干冠脉病变 SYNTAX CABG PCI TAVI 

    <International Circulation>: What is the next biggest challenges in this field?

  《国际循环》:在这一领域,下一个最大的挑战是什么?

    Dr. Eeckhout: In the field of revascularization I think that for interventional cardiologists the main issue is the bio-absorbable technology. The fully bio-absorbable stents, which will have limited release in Europe, will be a great breakthrough. I also see that the structural heart disease field as seeing great improvements. I would insist that TAVI, percutaneous treatment of aortic stenosis is an important progress. There are a lot of techniques, such as mitral valve replacement, seems to remain difficult but I think TAVI and progress in percutaneous revascularization devices are things that we will see in the next five to ten years.

    Eeckhout博士:在血运重建领域,我认为,对介入心脏病医生,主要问题是生物可吸收技术。将在欧洲限量发行的完全生物可吸收支架将会是一个很大的突破。我还看到,结构性心脏病领域有很大的进步。我坚持认为TAVI即主动脉瓣狭窄的经皮治疗是一个重大的进展。有很多技术,如二尖瓣置换术,似乎仍然是困难的,但我认为TAVI和经皮血运重建装置的进展是我们在未来五到十年将会看到的事情。



上一页  [1]  [2]  [3]  [4]  下一页

 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved